Leukemia Clinical Trial
Official title:
A Quality Improvement Project to Implement Psychosocial Care Standards in Clinical Practice in Pediatric Oncology "My Logbook! - I Know my Way Around!" ("Mein Logbuch - Ich Kenne Mich Aus!") Development and Evaluation of a Consensus and Evidence Based Psychosocial Therapy Tool in a Preliminary Psychosocial Study on Therapy Optimization.
Verified date | January 2024 |
Source | Medical University of Vienna |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, the main goal is to implement and evaluate a novel, evidence-based psycho-educative program for children in oncological care. Patients are provided with booklets tailored to each specific stage of their treatment. Among other factors, children's emotional well-being is evaluated as well as feasibility. The study is carried out at multiple sites across Austria, Germany and Italy/South Tirol.
Status | Completed |
Enrollment | 240 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 14 Years |
Eligibility | Inclusion Criteria experimental group: - currently or formerly treated for oncological condition - children/families at standard risk (Pediatric Psychosocial Preventative Health Model (PPPHM)) - at least average cognitive abilities (as measured via intelligence test) Inclusion Criteria control group: - currently or formerly treated for oncological condition Exclusion Criteria: - non-German speaking - Major vision impairments - Major auditive impairments |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University Graz | Graz | |
Austria | Kepler Universitätsklinikum | Linz | Oberösterreich |
Austria | Rehabilitationszentrum St. Veit im Pongau | St. Veit | Salzburg |
Austria | Medical University of Vienna | Vienna | |
Austria | St. Anna Kinderspital | Vienna | |
Germany | Klinik Bad Oexen | Bad Oeynhausen | |
Germany | Charité - Universitätsmedizin Berlin | Berlin | |
Germany | Luca-Dethlefsen-Hilfe e.V. | Bielefeld | |
Germany | Universitätsklinikum Carl Gustav Carus Dresden | Dresden | |
Germany | Universitätsklinikum Essen | Essen | Nordrhein-Westfalen |
Germany | Universitätsklinikum Frankfurt am Main | Frankfurt am Main | Hessen |
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Medizinische Hochschule Hannover | Hannover | Niedersachsen |
Germany | Universitätsklinikum des Saarlandes | Homburg | Saarland |
Germany | Universitätsklinikum Leipzig | Leipzig | Sachsen |
Germany | Universitätsklinikum Mannheim | Mannheim | |
Germany | Universitätsklinikum Münster | Münster | Nordrhein-Westfalen |
Germany | Universitätsklinikum Regensburg | Regensburg | |
Germany | Universitätsklinikum Tübingen | Tübingen | |
Germany | Universitätsklinikum Würzburg | Würzburg | |
Italy | Ospedale di Bolzano | Bolzano | Trentino-Alto Adige |
Switzerland | Inselspital, Universitätsspital Bern | Bern |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna | Charite University, Berlin, Germany, Cnopfsche Kinderklinik, Nürnberg, Goethe University, Hannover Medical School, Insel Gruppe AG, University Hospital Bern, Kepler University Hospital, Klinik Bad Oexen, Germany, Krankenhaus Bozen, Leuwaldhof St.Veit (Kinder- und Jugendreha), Luca-Dethlefsen-Hilfe e.V., Medical University of Graz, Salzburger Landeskliniken, St. Anna Kinderspital, Austria, Staedtisches Klinikum Karlsruhe, Universitätsklinikum Hamburg-Eppendorf, Universitätsklinikum Köln, Universitätsklinikum Leipzig, Universitätsmedizin Mannheim, University Hospital Carl Gustav Carus, University Hospital Erlangen, University Hospital Muenster, University Hospital Regensburg, University Hospital Schleswig-Holstein, University Hospital Tuebingen, University Hospital, Essen, University Hospital, Saarland, Wuerzburg University Hospital |
Austria, Germany, Italy, Switzerland,
Baxter S, Johnson M, Chambers D, Sutton A, Goyder E, Booth A. The effects of integrated care: a systematic review of UK and international evidence. BMC Health Serv Res. 2018 May 10;18(1):350. doi: 10.1186/s12913-018-3161-3. — View Citation
Kazak AE, Abrams AN, Banks J, Christofferson J, DiDonato S, Grootenhuis MA, Kabour M, Madan-Swain A, Patel SK, Zadeh S, Kupst MJ. Psychosocial Assessment as a Standard of Care in Pediatric Cancer. Pediatr Blood Cancer. 2015 Dec;62 Suppl 5:S426-59. doi: 10.1002/pbc.25730. — View Citation
Koch U, Mehnert A, Harter M. [Chronic somatic disorders and psychological comorbidity]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jan;54(1):1-3. doi: 10.1007/s00103-010-1196-7. No abstract available. German. — View Citation
Schröder HM, Lilienthal S, Schreiber-Gollwitzer BM, Griessmeier B, Leiss U. Psychosoziale Versorgung in der Pädiatrischen Onkologie und Hämatologie. PSAPOH (Hg.). 2013.
Schurman JV, Gayes LA, Slosky L, Hunter ME, Pino FA. Publishing quality improvement work in Clinical Practice in Pediatric Psychology: The "why" and "how to". Clinical Practice in Pediatric Psychology. 2015 Mar; 3(1):80.
Scialla MA, Canter KS, Chen FF, Kolb EA, Sandler E, Wiener L, Kazak AE. Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States. Pediatr Blood Cancer. 2018 Mar;65(3):10.1002/pbc.26869. doi: 10.1002/pbc.26869. Epub 2017 Oct 28. — View Citation
Stuber ML, Meeske KA, Krull KR, Leisenring W, Stratton K, Kazak AE, Huber M, Zebrack B, Uijtdehaage SH, Mertens AC, Robison LL, Zeltzer LK. Prevalence and predictors of posttraumatic stress disorder in adult survivors of childhood cancer. Pediatrics. 2010 May;125(5):e1124-34. doi: 10.1542/peds.2009-2308. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Emotional well-being, T1 | Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. | Based on the medical therapy protocol, after medical consultation, prior to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Emotional well-being, T2 | Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. | Post to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Emotional well-being, T3 | Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. | During, but before completion of treatment; prior to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Emotional well-being, T4 | Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. | During, post to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Emotional well-being, T5 | Patients' emotional well-being is evaluated using a visual array of emotional displays. Patients can choose three emotions that describe their current situation best. For analysis, emotions are categorized into positive, neutral, and negative emotions. Emotional well-being is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house, publication is pending. | During, but before completion of treatment - through study completion or end of medical treatment, an average of 1 year | |
Primary | Knowledgeability, T1 | Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. | Based on the medical therapy protocol, after medical consultation, prior to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Knowledgeability, T2 | Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. | Post to first session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Knowledgeability, T3 | Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. | During, but before completion of treatment; prior to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Knowledgeability, T4 | Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. | During, post to second session of the special issue (booklet) - through study completion or end of medical treatment, an average of 1 year | |
Primary | Knowledgeability, T5 | Patients are asked to rate their own knowledgeability regarding treatment, illness and hospital environment on a five-point scale ranging from "beginner" to "expert". Knowledgeability is evaluated longitudinally over multiple points of time. The diagnostic tool was developed in-house. | During, but before completion of treatment - through study completion or end of medical treatment, an average of 1 year | |
Primary | Feasibility of program | Rating of feasibility of the program by medical staff | Feasibility of program is evaluated following the second session which on average takes place one to six months after start of the treatment of the special issue (booklet). - through study completion or end of medical treatment, an average of 1 year | |
Secondary | Intelligence test | Patients are administered a standardized intelligence test, dependent on their age, e.g.
Wechsler Intelligence Scale for Children IV WISC-IV, Petermann & Petermann, 2014 or other comparable methods due to clinical standards |
During the first two months from diagnosis or start of psychosocial treatment - up to three Months | |
Secondary | Strengths and Difficulties Questionnaire (SDQ; Goodman, 1999) | The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire about 3-16 year olds. | During the first two months from diagnosis or start of psychosocial treatment - up to three Months | |
Secondary | KINDLR (Ravens-Sieberer & Bullinger, 2000) | The KINDLR is a standardized questionnaire for the assessment of quality of life in children and adolescents. | During the first two months from diagnosis or start of psychosocial treatment - up to three Months | |
Secondary | Questionnaire on Health Competence in Children and Adolescents, (Weiler, Fohn, Pletschko, Schwarzinger, & Leiss, 2017) | Questionnaire for the assessment of health competence in children and adolescents | During the first two months from diagnosis or start of psychosocial treatment - up to three Months | |
Secondary | Medical information | Diagnosis, date of diagnosis, pre-existing conditions, secondary conditions, form of treatment/therapy, psychiatric diagnoses, neurological status | Within the first week of treatment - up to three Months | |
Secondary | Demographic data | Age of patient, sex, parents' education, parents' profession, school form, mother language of patient | During the first two months from diagnosis or start of psychosocial treatment - up to three Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00858117 -
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
|
Phase 2 |